<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82491">
  <stage>Registered</stage>
  <submitdate>21/12/2007</submitdate>
  <approvaldate>7/01/2008</approvaldate>
  <actrnumber>ACTRN12608000001392</actrnumber>
  <trial_identification>
    <studytitle>Investigations into a TNF inhibitor to limit complications following complex surgery</studytitle>
    <scientifictitle>Investigations into a TNF inhibitor to limit complications following complex surgery</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Vascular surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A intravenous (IV) TNF inhibitor.
A single 100 ml dose of TNF inhibitor administered IV over 30 minutes, just prior to surgery. The control treatment is standard care. The follow up period will be 90 days.</interventions>
    <comparator>The control group will receive standard treatment. That is care routinely given to patients undergoing vascular surgery. No placebo will be given. The follow up period will be 90 days.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>TNF levels in blood tests</outcome>
      <timepoint>Blood tests will be taken at 1,2 and 4 hours following anaesthetic induction</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint>Total number of adverse events will be reviewed at 90 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Scheduled for elective vascular surgery</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>concurrent use of Interleukin-1 antagonist, septic arthritis in last 12 months, any infection, pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients on elective waiting list will be approached. Consent obtained. Randomized using random number computer sequence. No concealment of patients or treating doctors.</concealment>
    <sequence>Computer generated random numbers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>nil</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>4/04/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3065</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St.Vincent's Health Melbourne</primarysponsorname>
    <primarysponsoraddress>41 Victoria Pde,
Fitzroy, 3065
Melbourne
1</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National heart foundation</fundingname>
      <fundingaddress>Melbourne
411 King StreetWest 
Melbourne VIC 3003
Phone (03) 9329 8511</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will assess if a TNF inhibitor is safe to administer to patients undergoing vascular surgery. If so we will commence further trials to assess if a TNF inhibitor improves clinical outcomes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Health Melbourne</ethicname>
      <ethicaddress>41 Victoria Pde,
Fitzroy, 3065
Melbourne</ethicaddress>
      <ethicapprovaldate />
      <hrec>HREC-D 146/07</hrec>
      <ethicsubmitdate>14/12/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>St.Vincent's Health
41 Victoria Pde,
Fitzroy, 3065</address>
      <phone>0392884488</phone>
      <fax />
      <email>barry.dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>St.Vincent's Health,
41 Victoria Pde,
Fitzroy, 3065
Melbourne</address>
      <phone>0392884488</phone>
      <fax />
      <email>barry.dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>